Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-hour IOP-lowering Effect of 0.01% Bimatoprost
NCT01271686Phase 4Completed
- Sponsor
- University of California, San Diego
- Start
- Jan 2011
- Primary completion
- Oct 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bimatoprost in primary open-angle glaucoma (POAG) and ocular hypertension, sponsored by University of California, San Diego. Primary endpoint: Nocturnal Intraocular Pressure Change at 4 weeks. Started Jan 2011; status: completed.
02
Drugs
bimatoprost
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT01271686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01271686.